The Viral Vector & Plasmid DNA Manufacturing Market Size accounted for USD 5.4 Billion in 2023 and is estimated to achieve a ...

Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented Initiation of Phase 3 trial sites underway for pivotal study of IMNN-001 ...

Report Ocean’s latest analysis delves into the “Vietnam Viral Vector and Plasmid DNA Manufacturing Market” Report from 2024 to 2032, covering an array of market facets such as characteristics, size, ...

The combination of synchronous experimental process development and digital twin core model development is among the first of its kind.

Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD's Innovative Dual-Targeting CAR-T Therapy, 'P134 Cell Injection,' which has received Investigational New Drug (IND) ...

About IMNN-001 Immunotherapy Designed using IMUNON's proprietary TheraPlas ® platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables ...

Plasmid vectors pET11a-link-NGFP and pMRBAD ... before plating on kanamycin-containing media. Purify the vector products by electrophoresis through 0.8–1% agarose and determine the concentration ...

ProBio, a global contract development and manufacturing organization (CDMO), is pleased to announce the launch of its GMP ...